title: Therapeutic options for preservation of residual renal function in patients on peritoneal dialysis.
abstract: Dialysis is not the ideal renal replacement therapy because it does not fully restore all kidney functions. Increasing evidence suggests that preservation of residual renal function is associated with a survival benefit, a decrease in morbidity, better nutrition, a lower level of inflammatory markers, an improved quality of life, and cost savings by obviating the need for more peritoneal dialysis exchanges and possibly by reducing the requirement for antihypertensive agents, phosphate binders, and erythropoietin. In the present article, we review the impact of residual renal function on patient outcomes and the renoprotective strategies available in patients on peritoneal dialysis.
authors.affiliation: Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, PR China. philipli@cuhk.edu.hk
authors.forename: Philip Kamtao
authors.initials: PK
authors.lastname: Li
authors.forename: Yuk Lun
authors.initials: YL
authors.lastname: Cheng
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000008:administration & dosage; D015314:Dialysis Solutions / Q000494:pharmacology; D006801:Humans; D007022:Hypotension / Q000517:prevention & control; D007668:Kidney / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000503:physiopathology / Q000628:therapy*; D007677:Kidney Function Tests; D010530:Peritoneal Dialysis; D010538:Peritonitis / Q000517:prevention & control; D011379:Prognosis
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D003287:Contrast Media; D015314:Dialysis Solutions